Meritage Portfolio Management’s AstraZeneca AZN Stock Holding History

Meritage Portfolio Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-76,714	Closed	-$5.21M	–	176
2015 Q4	$5.21M	Sell	76,714 -5,390	-7%	-$353K	0.59%	72
2015 Q3	$5.23M	Sell	82,104 -7,442	-8%	-$490K	0.61%	62
2015 Q2	$5.71M	Sell	89,546 -745	-0.8%	-$51K	0.6%	60
2015 Q1	$6.18M	Buy	90,291 +5,255	+6%	+$365K	0.62%	49
2014 Q4	$5.99M	Buy	85,036 +2,955	+4%	+$212K	0.64%	48
2014 Q3	$5.86M	Buy	82,081 +1,325	+2%	+$97K	0.67%	45
2014 Q2	$6M	Buy	80,756 +4,565	+6%	+$330K	0.65%	44
2014 Q1	$4.94M	Buy	76,191 +1,855	+2%	+$120K	0.59%	70
2013 Q4	$4.41M	Buy	74,336 +265	+0.4%	+$14.4K	0.55%	82
2013 Q3	$3.85M	Buy	74,071 +1,570	+2%	+$78.9K	0.5%	102
2013 Q2	$3.43M	Buy	+72,501	New	+$3.69M	0.49%	105

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

Cambiar Investors Denver, Colorado $2.3B AUM 24.77% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

SCCM

Schafer Cullen Capital Management New York $491M AUM 41.48% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Meritage Portfolio Management's AZN Position: Q1 2016 in Review

Meritage Portfolio Management sold out of AstraZeneca (AZN) in Q1 2016, closing a stake of 76,714 shares — an estimated $5.21M sold.

Meritage Portfolio Management first reported a position in AZN in Q2 2013 and held it in 11 quarters. The position peaked at $6.18M in Q1 2015. 390 funds tracked by Wall St. Rank hold AZN as of Q1 2016.

Meritage Portfolio Management reported no remaining AstraZeneca position as of Q1 2016 after selling out during the quarter.
Meritage Portfolio Management sold 76,714 AstraZeneca shares in Q1 2016, an estimated $5.21M.
Meritage Portfolio Management first reported a position in AstraZeneca in Q2 2013 and held it in 11 quarters.
Meritage Portfolio Management's AstraZeneca position peaked at $6.18M in Q1 2015.
390 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2016.

Based on Meritage Portfolio Management's 13F filing for Q1 2016, filed 21 Apr 2016.